DARA is about to be acquired by UK-listed Midatech Pharma. At the current share price DARA trades at a 16% discount to Midatech’s offer, likely due to a lack of shareholders interest. Its shareholders will vote on this deal on Wednesday making it an attractive short term play. Read more.
KBIO’s share price went from $ 0.20 to $ 18.25 after Martin Shkreli bought a majority stake. Shkreli is in it for a drug called Lenzilumab, which is yet to prove its effectiveness. KBIO shares seem expensive and are essentially a bet on Shkreli himself. Yet there are better biotech-shorts out there. Read more.
EURI has seen unusual high trading activity as a result of a big stock promotion this month. However, the company hardly generates any revenue despite a market cap of 130M. Millions of shares issued at almost zero are waiting to be sold in the open market. Read more.